Blog
RSS FeedPosted by Michael Wonder on 19 Jan 2023
Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS
18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert ...
Posted by Michael Wonder on 20 Dec 2022
Radicava (edaravone) oral suspension receives positive recommendation from INESSS for the treatment of patients with ALS
19 December 2022 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the Institut national d'excellence en ...
Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 07 Nov 2022
Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults
3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 ...
Posted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 22 Sep 2022
CADTH recommendation to not reimburse new treatment a failure for people living with schizophrenia
21 September 2022 - The Schizophrenia Society of Canada is joined by the schizophrenia community across Canada in its disappointment with ...
Posted by Michael Wonder on 13 Sep 2022
CADTH partners with international health technology assessment bodies to boost collaboration on shared challenges
6 September 2022 - Six health technology assessment bodies from three continents will join forces to collaborate on a range of ...
Posted by Michael Wonder on 01 Sep 2022
CADTH launches post-market drug evaluation program
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
Posted by Michael Wonder on 01 Sep 2022
Vabysmo (faricimab injection) receives positive CADTH recommendation for the treatment of neovascular (wet) age-related macular degeneration in adults
1 September 2022 - Provincial jurisdictions will make the final decision on public reimbursement. ...
Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
Posted by Michael Wonder on 09 Aug 2022
Network collaborators announced for CADTH’s post-market drug evaluation network
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
Posted by Michael Wonder on 09 Aug 2022
Introducing CADTH’s RWE Guidance Working Group
9 August 2022 - CADTH is pleased to announce the introduction of the Real-World Evidence Guidance Working Group. ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 16 Jun 2022
Core network partners announced for CADTH’s post-market drug evaluation network
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...